---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-104616"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2022-09-30T23:59:59+00:00"
generated_at: "2026-06-23T06:22:39.144586+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nasdaq Panel grants Avenue Therapeutics extension to Oct 31 to meet equity requirement, Oct 6 for bid price

## Summary
- Nasdaq Hearings Panel granted continued listing through Oct 31, 2022 to demonstrate compliance with stockholders' equity minimum of $2.5M.
- Company must also satisfy minimum bid price of $1.00 per share by Oct 6, 2022.
- Previously, Company was non-compliant with both Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1).
- Hearing request on Aug 16, 2022 stayed suspension until Panel decision on Sep 29.

## SEC filing metadata
- accession: 0001104659-22-104616
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2022-09-30T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465922104616/0001104659-22-104616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465922104616/tm2227168d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-104616
- JSON: https://secwatch.observer/filing/0001104659-22-104616.json
- Plain text: https://secwatch.observer/filing/0001104659-22-104616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.